CA3073991A1 - Use of neuropeptide drug for treatment of cadasil - Google Patents

Use of neuropeptide drug for treatment of cadasil Download PDF

Info

Publication number
CA3073991A1
CA3073991A1 CA3073991A CA3073991A CA3073991A1 CA 3073991 A1 CA3073991 A1 CA 3073991A1 CA 3073991 A CA3073991 A CA 3073991A CA 3073991 A CA3073991 A CA 3073991A CA 3073991 A1 CA3073991 A1 CA 3073991A1
Authority
CA
Canada
Prior art keywords
cerebrolysin
cadasil
use according
treated
concentrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3073991A
Other languages
English (en)
French (fr)
Inventor
Stefan Winter
Herbert Moessler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ever Neuro Pharma GmbH
Original Assignee
Ever Neuro Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ever Neuro Pharma GmbH filed Critical Ever Neuro Pharma GmbH
Publication of CA3073991A1 publication Critical patent/CA3073991A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
CA3073991A 2017-08-28 2018-08-28 Use of neuropeptide drug for treatment of cadasil Pending CA3073991A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17188180.8 2017-08-28
EP17188180.8A EP3449931B1 (en) 2017-08-28 2017-08-28 Use of cerebrolysin
PCT/EP2018/073106 WO2019042983A1 (en) 2017-08-28 2018-08-28 USE OF CERBROLYSINE

Publications (1)

Publication Number Publication Date
CA3073991A1 true CA3073991A1 (en) 2019-03-07

Family

ID=59745228

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073991A Pending CA3073991A1 (en) 2017-08-28 2018-08-28 Use of neuropeptide drug for treatment of cadasil

Country Status (15)

Country Link
US (1) US12589118B2 (enExample)
EP (2) EP3449931B1 (enExample)
JP (1) JP7281450B2 (enExample)
KR (1) KR102676274B1 (enExample)
CN (1) CN111050780B (enExample)
AU (1) AU2018326339A1 (enExample)
CA (1) CA3073991A1 (enExample)
EA (1) EA202090108A1 (enExample)
ES (2) ES2767070T3 (enExample)
HR (1) HRP20200031T1 (enExample)
MX (1) MX2020002267A (enExample)
PH (1) PH12020500376A1 (enExample)
PL (2) PL3449931T3 (enExample)
UA (1) UA129400C2 (enExample)
WO (1) WO2019042983A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220168325A1 (en) * 2019-03-25 2022-06-02 The University Of Vermont Methods to promote cerebral blood flow in the brain
ES2964145T3 (es) 2020-07-13 2024-04-04 Ever Neuro Pharma Gmbh Método para producir un hidrolizado de proteína de cerebro de mamífero
KR20240159455A (ko) * 2021-06-02 2024-11-05 리제너론 파마슈티칼스 인코포레이티드 신경성 유전자좌 노치 상동체 단백질 3(notch3) 제제를 이용한 뇌혈관 질환의 치료

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126563T2 (de) 1990-04-12 1998-02-05 Ebewe Arzneimittel Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia
EP1857463A1 (en) * 2006-05-03 2007-11-21 Ebewe Pharma Ges.m.b.H. Nfg. KG Peptide having neuroprotective effects
CA2734646C (en) 2008-08-20 2016-06-28 James W. Mcginity Hot-melt extrusion of modified release multi-particulates

Also Published As

Publication number Publication date
EP3449931A1 (en) 2019-03-06
HRP20200031T1 (hr) 2020-03-20
EP3675879B1 (en) 2021-09-15
PL3675879T3 (pl) 2022-02-14
CN111050780A (zh) 2020-04-21
WO2019042983A1 (en) 2019-03-07
CN111050780B (zh) 2023-11-03
KR20200045503A (ko) 2020-05-04
PH12020500376A1 (en) 2020-12-07
EA202090108A1 (ru) 2020-03-31
PL3449931T3 (pl) 2020-06-01
MX2020002267A (es) 2020-10-22
EP3449931B1 (en) 2019-10-16
US20200376040A1 (en) 2020-12-03
ES2767070T3 (es) 2020-06-16
JP2020531568A (ja) 2020-11-05
JP7281450B2 (ja) 2023-05-25
US12589118B2 (en) 2026-03-31
ES2901508T3 (es) 2022-03-22
EP3675879A1 (en) 2020-07-08
AU2018326339A1 (en) 2020-03-05
KR102676274B1 (ko) 2024-06-18
UA129400C2 (uk) 2025-04-16

Similar Documents

Publication Publication Date Title
US10758598B2 (en) TPP-1 formulations and methods for treating CLN2 disease
EP3675879B1 (en) Cerebrolysin for use in the treatment of cadasil
Broussalis et al. Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies
Ha et al. AAV2-mediated GRP78 transfer alleviates retinal neuronal injury by downregulating ER stress and tau oligomer formation
Dhapola et al. Exploring Retinal Neurodegeneration in Alzheimer’s Disease: A Molecular and Cellular Perspective
Gentile et al. Cluster headache attacks and multiple sclerosis
Khan et al. Fingolimod-associated macular edema in the treatment of multiple sclerosis
HK40026040B (en) Cerebrolysin for use in the treatment of cadasil
EA040978B1 (ru) Применение церебролизина
Cordano et al. Inflammation in the anterior visual pathway in multiple sclerosis: what do the animal models teach us?
HRP20220370A1 (hr) Postupci liječenja cln2 bolesti kod pedijatrijskih subjekata
WO2022061812A1 (zh) 醋酸格拉替雷在制备Aβ42毒性抑制剂和清除剂中的应用
Wang et al. Age-and Sex-Specific Regulation of Serine Racemase in the Retina of an Alzheimer's Disease Mouse
Ramos Pérez et al. Inflammation in the anterior visual pathway in multiple sclerosis: what do the animal models teach us?
Kogo et al. Transient Retinal Vessel Whitening After Whole-Ventricle Radiotherapy
Corey-Bloom et al. O1-05-01 The safety and efficacy of an extended-release formulation of galantamine (reminyl ER) in the treatment of Alzheimer's disease
Cordano et al. USA. 4Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa 16132, Italy. 5IRCCS Ospedale Policlinico San Martino, Genoa 16132, Italy. 6Department of Neurology, S. Paolo Hospital, Savona 17100, Italy.
BR122025005065A2 (pt) Formulações e composições de tpp1, bem como uso no tratamento de doença lcn2
BR112017023805B1 (pt) Formulações e composições de tpp1, bem como uso no tratamento de doença lcn2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220916

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226